Abstract:Abstract Background Aildenafil citrate is a potent and selective inhibitor of cyclic guanosine monophosphate–specific phosphodiesterase type 5, developed for the treatment of erectile dysfunction (ED). Aim This study aimed to assess the pharmacokinetics, safety, and tolerability of aildenafil citrate tablets after multiple doses in healthy Chinese males. Methods Twenty participants were divided into 2 groups, 10 participants each. Participants were administered multiple doses of aildenafil citrate tablets at 30 and 60 mg. Outcomes The safety evaluation was based on clinical symptoms and adverse events. Concentrations of aildenafil and its key metabolites (M1, M5, and M12) in human serum were measured by liquid chromatography–tandem mass spectrometry. Results Pharmacokinetic analysis showed rapid absorption and elimination of aildenafil, with a median time to maximum serum concentration of 1 hour and mean terminal half-lives of 2.75 and 3.26 hours in the respective dose groups. The mean maximum concentration was proportional to the aildenafil dose in the range of 30 to 60 mg, although the area under the curve was not proportional for serum concentration vs time 0 to the last measurable time point (24 hours). Multiple doses of aildenafil were well tolerated, with 60.0% of men experiencing treatment-emergent adverse events, notably myalgia and fatigue, particularly in the 60-mg group. Clinical Implications Aildenafil citrate tablets demonstrated favorable tolerability with once-daily administration over the clinical dose range. The occurrence of myalgia and fatigue was more prevalent in the 60-mg group. From a pharmacokinetic perspective, optimal administration of aildenafil citrate tablets appears to be 1 hour before sexual intercourse in men with ED. Strengths and Limitations This study presents robust safety and pharmacokinetic data at expected therapeutic doses, unaffected by clinical factors. The efficacy of aildenafil citrate tablets warrants further validation in individuals with ED. Conclusion Aildenafil citrate tablets exhibited good tolerability in healthy Chinese males following multiple doses at 30 and 60 mg. The 60-mg group showed an increased incidence of myalgia and fatigue, suggesting the need for heightened clinical vigilance. The mean maximum concentration, but not the area under the curve, displayed dose proportionality within the 30- to 60-mg dose range, and no significant drug accumulation was observed with repeated daily administration. Clinical Trial Registration CTR20192473 (http://www.chinadrugtrials.org.cn).

Safety of Sildenafil in Men with Cardiovascular Diseases

Progress in Research into Use of Sildenafil Citrate in Cardiovascular Disease

Using of sildenafil citrate in treatment of erectile dysfunction patients with cardiovascular disease

[Advances in Application of Sildenafil to Erectile Dysfunction].

Efficacy and Safety of Oral Sildenafil in the Treatment of Erectile Dy Sfunction

Effect of Sildenafil on Erectile Dysfunction and Improvement in the Quality of Sexual Life in China: a Multi-Center Study.

Clinical experience of sildenafil oral therapy for male erectile dysfunction

Function of sildenafil on diseases other than urogenital system: An umbrella review

[Safety and Efficacy of China-made Sildenafil Citrate in the Treatment of Erectile Dysfunction].

Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases

Efficacy and Safety of Aildenafil Citrate in Chinese Men with Erectile Dysfunction: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial

Risk factors for erectile dysfunction in patients with cardiovascular disease

Study on Efficacy and Safety of Oral Sildenafil Citrate in the Treatment of Erectile Dysfunction

[Effects of Sildenafil on Erectile Dysfunction in the Aged Men with Diabetes].

Should Patients with Erectile Dysfunction Be Evaluated for Cardiovascular Disease?

Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety

Sildenafil-associated hepatoxicity: a review of the literature

[Efficacy and Safety of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction].

Impact of Sildenafil Therapy on Pulmonary Arterial Hypertension in Adults with Congenital Heart Disease

Erectile dysfunction and cardiovascular risk: a review of current findings.

Safety, tolerability, and pharmacokinetics of aildenafil citrate tablets, a novel oral PDE5 inhibitor, in healthy Chinese volunteers after multiple-dose administration